Quality of life and swallowing with standard chemoradiotherapy versus accelerated radiotherapy and panitumumab in locoregionally advanced carcinoma of the head and neck: A phase III randomised trial from the Canadian Cancer Trials Group (HN.6)

•Three hundred twenty head and neck cancer patients participated in a phase III randomised trial comparing standard radiotherapy /cisplatin with accelerated radiotherapy/panitumumab.•Quality of life (QOL) and swallowing outcomes were compared between arms.•No clinically important differences by arm were seen 2–36 months post-treatment.•Swallowing and head and neck–specific QOL showed persistent declines in both study arms.•These results do not suggest adopting the experimental arm to improve QOL.